Roche agreed to acquire PathAI in a deal valued at $750 million upfront, aiming to accelerate AI-powered digital pathology across pathology laboratories and biopharma workflows. The transaction targets a practical bottleneck in translational pipelines: turning pathology data into consistent, high-quality quantitative inputs for development programs. PathAI’s platform has been positioned as a way to improve image analytics and support decision-making in clinical trials and diagnostics. For Roche, the move reinforces a broader strategy of embedding AI into core R&D operations, rather than relying solely on internal tools. The size and upfront structure of the transaction signals Roche’s willingness to pay for near-term capability in imaging AI, as digital pathology becomes a larger component of evidence generation for targeted therapies.